Sustained weight loss with vagal nerve blockade but not with sham: 18‐month results of the recharge trial

SA Shikora, BM Wolfe, CM Apovian, M Anvari… - Journal of …, 2015 - Wiley Online Library
Background/Objectives. Vagal block therapy (vBloc) is effective for moderate to severe
obesity at one year. Subjects/Methods. The ReCharge trial is a double‐blind, randomized …

Two-year outcomes of vagal nerve blocking (vBloc) for the treatment of obesity in the ReCharge trial

CM Apovian, SN Shah, BM Wolfe, S Ikramuddin… - Obesity surgery, 2017 - Springer
Abstract Background The ReCharge Trial demonstrated that a vagal blocking device (vBloc)
is a safe and effective treatment for moderate to severe obesity. This report summarizes 24 …

Effect of vagal nerve blockade on moderate obesity with an obesity-related comorbid condition: the ReCharge study

JM Morton, SN Shah, BM Wolfe, CM Apovian, CJ Miller… - Obesity surgery, 2016 - Springer
Background Vagal nerve blockade (vBloc) therapy was shown to be a safe and effective
treatment for moderate to severe obesity. This report summarizes the safety and efficacy of …

The EMPOWER study: randomized, prospective, double-blind, multicenter trial of vagal blockade to induce weight loss in morbid obesity

MG Sarr, CJ Billington, R Brancatisano, A Brancatisano… - Obesity surgery, 2012 - Springer
Background Intermittent, reversible intraabdominal vagal blockade (VBLOC® Therapy)
demonstrated clinically important weight loss in feasibility trials. EMPOWER, a randomized …

Effect of reversible intermittent intra-abdominal vagal nerve blockade on morbid obesity: the ReCharge randomized clinical trial

S Ikramuddin, RP Blackstone, A Brancatisano, J Toouli… - Jama, 2014 - jamanetwork.com
Importance Although conventional bariatric surgery results in weight loss, it does so with
potential short-term and long-term morbidity. Objective To evaluate the effectiveness and …

Intermittent vagal nerve block for improvements in obesity, cardiovascular risk factors, and glycemic control in patients with type 2 diabetes mellitus: 2-year results of …

SA Shikora, J Toouli, MF Herrera, B Kulseng… - Obesity surgery, 2016 - Springer
Background One-year results of the VBLOC DM2 study found that intermittent vagal blocking
(VBLOC therapy) was safe among subjects with obesity and type 2 diabetes mellitus (T2DM) …

Vagal blocking improves glycemic control and elevated blood pressure in obese subjects with type 2 diabetes mellitus

S Shikora, J Toouli, MF Herrera, B Kulseng… - Journal of …, 2013 - Wiley Online Library
Background. An active device that downregulates abdominal vagal signalling has resulted
in significant weight loss in feasibility studies. Objective. To prospectively evaluate the effect …

Vagal blocking for obesity control: a possible mechanism-of-action

H Johannessen, D Revesz, Y Kodama, N Cassie… - Obesity surgery, 2017 - Springer
Abstract Background Recently, the US FDA has approved “vagal blocking therapy or
vBLoc® therapy” as a new treatment for obesity. The aim of the present study was to study …

Intra-abdominal vagal blocking (VBLOC therapy): clinical results with a new implantable medical device

M Camilleri, J Toouli, MF Herrera, B Kulseng, L Kow… - Surgery, 2008 - Elsevier
BACKGROUND: A new medical device uses high-frequency electrical algorithms to create
intermittent vagal blocking (VBLOC therapy). The aim is to assess the effects of vagal …

A systematic review on neuromodulation therapies for reducing body weight in patients with obesity

FV Gouveia, E Silk, B Davidson, CB Pople… - Obesity …, 2021 - Wiley Online Library
The global prevalence of obesity increases yearly along with a rising demand for efficacious,
safe, and accessible treatments. Neuromodulation interventions (ie, deep brain stimulation …